Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: Identification of modification sites by mass spectrornetry

被引:25
|
作者
Wen, B
Doneanu, CE
Gartner, CA
Roberts, AG
Atkins, WM
Nelson, SD
机构
[1] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
关键词
D O I
10.1021/bi048228c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
While photoaffinity ligands (PALs) have been widely used to probe the structures of many receptors and transporters, their effective use in the study of membrane-bound cytochrome P450s is less established. Here, lapachenole has been used as an effective photoaffinity ligand of human P450 3A4, and mass spectrometry data demonstrating the efficient and specific photoaffinity labeling of CYP3A4 by this naturally occurring benzochromene compound is presented. Without photolysis, lapachenole is a substrate of CYP3A4 and can be metabolized to hydroxylated products by this enzyme. A high-performance liquid chromatography/electrospray ionization mass spectrometry (HPLC/ESI-MS) procedure was developed to analyze small amounts of intact purified CYP3A4, and analysis of the labeled protein showed the presence of one molecule of lapachenole bound per monomer of protein. Photolabeled CYP3A4 peptide adducts were further characterized by mass spectrometric analysis after proteolytic digestion and isolation of fluorescent photolabeled peptides. Two peptide adducts accounting for >95% of the labeled peptides were isolated by HPLC, and both peptides, ECYSVFTNR (positions 97-105) and VLQNFSFKPCK (positions 459-469), were identified by nano-LC/ESI quadrupole time-of-flight (QTOF) and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. The sites of modification were further localized to positions Cys-98 and Cys-468 for each peptide by nano-LC/ESI QTOF tandem mass spectrometry (MS/MS). The results provided the first direct evidence for interaction between the PAL and the putative B-B' loop region, which may serve as a substrate access channel or as a part of the CYP3A4 active site. In conclusion, benzochromene analogues are effective PALs, which may be used in the study of other cytochrome P450 structures.
引用
收藏
页码:1833 / 1845
页数:13
相关论文
共 50 条
  • [22] Mass spectrometry identification of cytochrome P450 2B4 interaction sites for NADPH: Cytochrome P450 reductase
    Ivanov A.V.
    Kopylov A.T.
    Zgoda V.G.
    Toropygin I.Y.
    Khryapova E.V.
    Ivanov Y.D.
    Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2009, 3 (4) : 361 - 371
  • [23] Identification of epitopes on cytochrome P450 3A4/5 recognized by monoclonal antibodies
    Parimoo, B
    Mishin, VM
    Busch, CM
    Thomas, PE
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 414 (02) : 244 - 254
  • [24] A MECHANISM BASED MODEL OF STEROIDS METABOLIC SITES PREDICTION FOR CYTOCHROME P450 3A4
    Dai, Ziru
    Ai, Chunzhi
    Ge, Guangbo
    Man, Huizi
    Jia, Yan
    Yang, Ling
    DRUG METABOLISM REVIEWS, 2014, 45 : 160 - 160
  • [25] Modification of cytochrome P450 3A4 by soft electrophiles leads to differential residual activity
    Rock, Dan A.
    Davis, John A.
    VandenBrink, Brooke M.
    DRUG METABOLISM REVIEWS, 2011, 43 : 67 - 67
  • [26] Kinetics of electron transfer between NADPH-cytochrome P450 reductase and cytochrome P450 3A4
    Farooq, Yassar
    Roberts, Gordon C. K.
    BIOCHEMICAL JOURNAL, 2010, 432 : 485 - 493
  • [27] Identification of Binding Hot Spots of Cytochrome P450 3A4 by Computational Solvent Mapping
    Chuang, Gwo-Yu
    Kozakov, Dima
    Brenke, Ryan
    Vajda, Sandor
    CHEMICAL RESEARCH IN TOXICOLOGY, 2008, 21 (12) : 2452 - 2452
  • [28] Development of cytochrome P450 3A4 inhibition model.
    Arimoto, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U1019 - U1020
  • [29] Regioselectivity preference of testosterone hydroxylation by cytochrome P450 3A4
    Yan Zhang
    Phani Morisetti
    Jeffery Kim
    Lynelle Smith
    Hai Lin
    Theoretical Chemistry Accounts, 2008, 121 : 313 - 319
  • [30] Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
    Bottorff, M
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (08): : 1042 - 1043